China’s Antengene raises $120m Series B round
Antengene Corporation, a Chinese biopharmaceutical company focused on oncology drugs and therapies, has raised $120 million in a Series B round led by Boyu Capital and FountainVest Partners.
Other participants include Celgene Corporation, WuXi Corporate Venture Fund, Taikang Insurance Group, and existing investors Qiming Venture Partners and TF Capital. The company raised a $21 million Series...
More on Greater China
Latest News
China's Black Sesame completes Series C with $500m haul
Black Sesame Technologies, a China-based chipmaker specializing in autonomous driving applications, has closed a Series C extension led by SummitView Capital. This brings the size of the overall round to USD 500m.
J-Star invests Japanese courier business
Japanese lower middle-market private equity firm J-Star has made an investment of undisclosed size in air cargo transportation and courier services provider Score Japan Holdings.
Gaorong, Tsing Song back China CDMO IntellectiveBio
Gaorong Capital and Tsing Song Capital have led a CNY 500m (USD 74m) Series C for IntellectiveBio, a China-based contract development and manufacturing organisation (CDMO).
Morningside joins round for China's Epigenic Therapeutics
Morningside Venture Capital has teamed up with Kingray Capital, Trinity Innovation Fund, TigerYeah Capital, and FountainBridge Capital to provide USD 20m in angel and pre-Series A funding for Epigenic Therapeutics, a China-based gene editing specialist.